Compare Quest Diagnostics Inc (DGX) vs Twilio Inc (TWLO) Price & Performance

Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.

The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.

Twilio (TWLO) trades at $275.77, up 1.01% with a bullish technical signal. The company shows strong fundamental improvement with revenue growing from $3.8B in 2022 to $5.1B in 2025, achieving positive net income of $34M after years of losses. Recent Q2 2026 earnings beat expectations with EPS of $1.47 versus $1.32 expected. The stock's inclusion in the S&P 500 index effective October 6, 2026, provides institutional validation and potential index fund inflows.

Twilio presents a compelling growth story with accelerating revenue and profitability, though valuation remains elevated at P/E 38.09. Key risks include competitive pressures in customer engagement software and execution challenges in maintaining growth momentum. Analyst consensus remains strongly bullish with 77% buy ratings, though the current price exceeds the $254.65 consensus target, suggesting near-term caution may be warranted despite positive long-term prospects.